Thyssen JP, Yosipovitch G, Paul C, et al. - In moderate-to-severe atopic dermatitis (AD) patients, both abrocitinib doses (200 and 100 mg) conferred significant improvements in patient-reported outcomes, compared with placebo. Numerically greater effects were seen with abrocitinib 200 mg vs dupilumab.

• In JADE COMPARE (a multicenter, phase 3 randomized, double-blind, placebo-controlled trial), adults with moderate-to-severe AD were randomly assigned to receive 16 weeks of oral abrocitinib 200 or 100 mg once daily, dupilumab 300 mg subcutaneous injection every 2 weeks, or placebo, with background topical therapy.

• For 200 and 100 mg abrocitinib, the proportion of patients achieving Patient-Oriented Eczema Measure scores <3 at week 16 was 21.3% and 11.7%, respectively; estimate was 12.4% for dupilumab, and 4.8% for placebo.

• Relative to baseline, the proportion of patients exhibiting ≥4-point improvement in Night Time Itch Scale severity was 64.3% and 52.4% for 200 and 100 mg abrocitinib, 54.0% for dupilumab, and 34.4% for placebo.

• A ≥4-point improvement from baseline in Dermatology Life Quality Index was achieved in 85.0% and 74.4% of patients treated with 200 and 100 mg abrocitinib, 83.4% for dupilumab, and 59.7% for placebo.